Click here to receive MS news via e-mail
Publish date: December 14, 2016
By: Jeff Evans
Frontline Medical News
Frontline Medical News
Key clinical point: Extending the dosing interval of natalizumab
to a maximum of 8 weeks in order to lower its serum concentration may not do
anything to reduce the risk of PML.
to a maximum of 8 weeks in order to lower its serum concentration may not do
anything to reduce the risk of PML.
Major finding: A total of 10 control patients had a mean
natalizumab serum concentration of 23.8 mcg/mL, which was in the same range as
the 18.9 mcg/mL level observed in 5 patients before a diagnosis of PML.
natalizumab serum concentration of 23.8 mcg/mL, which was in the same range as
the 18.9 mcg/mL level observed in 5 patients before a diagnosis of PML.
Data source: A comparison of 5 patients with PML and 10 age-
and sex-matched controls from a prospective cohort of 219 patients with
relapsing-remitting MS who were treated with natalizumab at one center.
and sex-matched controls from a prospective cohort of 219 patients with
relapsing-remitting MS who were treated with natalizumab at one center.
Disclosures: The study received support from the Brain
Foundation Netherlands. Five of the authors reported financial ties to various
pharmaceutical companies that market MS drugs, including Biogen, which markets
natalizumab.
Foundation Netherlands. Five of the authors reported financial ties to various
pharmaceutical companies that market MS drugs, including Biogen, which markets
natalizumab.
Read complete article here
MS Views and News
Providing educational information, resources and services for those affected by MS
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews